Dr. Goy on CAR T-Cell Therapy Updates in Non-Hodgkin Lymphoma

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

Many of the studies presented at the 2019 ASCO Annual Meeting related to CAR T-cell therapy were trials in progress. However, one study that had data read out included a subset from the ZUMA-1 trial, which demonstrated promising efficacy and safety data in patients older than 65 years with axicabtagene ciloleucel (Yescarta). Moreover, in the TRANSCEND NHL 001 trial, lisocabtagene maraleucel, another CAR T-cell product, also demonstrated benefit in patients with relapsed/refractory mantle cell lymphoma.

In patients with relapsed/refractory central nervous system lymphoma, data also showed that CAR T-cell therapy is feasible and demonstrated preliminary activity.

<<< 2019 ASCO Annual Meeting